Trevi Therapeutics, Inc. Skyrocketed

Tue, Mar 31, 2020 at 05:30 PM
Trevi Therapeutics, Inc. Skyrocketed

Trevi Therapeutics, Inc. (TRVI:NASDAQ) rocketted at $3.29, a gain of 92.4%. On Mon 30 Mar 20, TRVI:NASDAQ touched a New 2-Week Low of $1.71. The stock appeared on our News Catalysts scanner on Tue 17 Mar 20 at 04:08 AM in the 'INVESTOR UPDATE' category. From Mon 16 Mar 20, the stock recorded 40.00% Up Days and 54.55% Green Days

About Trevi Therapeutics, Inc. (TRVI:NASDAQ)

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.

Share
Get 50% Off Premium Subscription
$19.99 USD
Limited-Time Discount
Your price will remain at $9.99 USD after the discount period
$9.99 USD
monthly
Signup 7 Days Trial. No Credit Card Required!
Ever wanted to explore stocks that have recently spiked... stocks moving sideways... or other trends? You're in the right place! Check StockTreats features.